Clinical trial · Observational
Role of BMP Pathway in MDS Progression
Role of the BMP Pathway in Myelodysplastic Syndromes Progression and in the Transition to Acute Myeloid Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Myelodysplastic syndromes (MDS) are hematological cancers that can progress to acute myelogenous leukemia (AML). The involvement of the microenvironment in the maintenance, resistance and evolution of MDS is increasingly described. The Bone Morphogenetic Protein (BMP) pathway is involved in numerous functions, including self-renewal of the hematopoietic stem cell compartment and the regulation of hematopoiesis, via interaction with bone marrow stromal cells. Investigators have demonstrated its involvement in chronic myeloid leukemia (CML) and AML, in particular via the activation of TWIST1, ΔNp73, NANOG; it is responsible for an increased state of quiescence of certain cancer stem cells and their resistance. Preliminary results based on the analysis of large databases suggest that the BMP pathway is also altered early in MDS. This study explores the alteration of this pathway in MDS and its involvement in the transformation into AML. If appropriate, the BMP pathway could constitute a very promising therapeutic target to combat transformation into AML.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myelogenous Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- MDS patients
- description
- Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization: * one or more cytopenias, * and/or dysplasia of one or more lines, * and/or bone marrow blastosis * and/or sideroblasts in medullary crowns * and/or genetic/cytogenetic abnormalities characteristic of MDS. * Whatever the R-IPSS stage (Revised International Prognostic Scoring System) * No history of cytotoxic treatment (hydroxycarbamide, azacytidine)
- interventionNames
- Biological: Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
- label
- AML patients
- description
- Adult patients with suspected de novo acute myeloid leukemia at initial management
- interventionNames
- Biological: Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
Primary outcomes (5)
- measure
- Descriptive analysis of the BMP pathway : Bone marrow plasma BMP2/BMP4 levels
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization Or * Adult patient with suspicion of de novo acute myeloid leukemia at initial treatment Exclusion Criteria: * Frontier MDS/myeloproliferative syndromes including chronic myelomonocytic leukemia * MDS and AML having already benefited from cytotoxic treatment including hydroxycarbamide, azacytidine, intensive chemotherapy * Patients objecting to their inclusion in the study * Pregnant or breastfeeding women * Patients under legal protection measure
References
Publications (0)
Data not yet available